专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013055829A1 PROXIMITY-BASED ASSAYS FOR THE DETECTION OF SIGNALING PROTEIN EXPRESSION AND ACTIVATION 审中-公开
标题翻译：用于检测信号蛋白表达和激活的基于接近度的测定
公开(公告)号：WO2013055829A1
公开(公告)日：2013-04-18
申请号：PCT/US2012/059610
申请日：2012-10-10
申请人： NESTEC S.A. , BAETGE, Edward , KIM, Phillip , SINGH, Sharat
发明人： BAETGE, Edward , KIM, Phillip , SINGH, Sharat
IPC分类号： G01N33/53 , C12N15/115
CPC分类号： C12N15/115 , C12N2310/16 , C12N2310/3517 , C12N2320/10 , G01N33/6893 , G01N2440/10 , G01N2440/12 , G01N2440/14 , G01N2800/02 , G01N2800/50
摘要： The present invention provides methods for detecting or measuring the expression and/or activation levels of one or a plurality of signaling proteins in samples obtained from patients in a specific, multiplex, high-throughput assay. By detecting any alterations (e.g., dysregulated expression and/or activation) in one or more signaling proteins of interest, the present invention is particularly advantageous for aiding the prediction, diagnosis, prognosis, and/or monitoring of a pre-disease state (e.g., pre-metabolic syndrome such as pre-diabetes), a cancer, and/or a metabolic disorder (e.g., diabetes such as type 1 or type 2 diabetes).
摘要翻译：本发明提供用于在特异性，多重，高通量测定中检测或测量从患者获得的样品中的一种或多种信号传导蛋白的表达和/或活化水平的方法。通过检测感兴趣的一种或多种信号传导蛋白中的任何改变（例如，失调的表达和/或激活），本发明特别有利于帮助疾病前状态的预测，诊断，预后和/或监测（例如，，前代谢综合征如前期糖尿病），癌症和/或代谢紊乱（例如，糖尿病如1型或2型糖尿病）。

2. 发明申请

WO2013033623A9 PROFILING OF SIGNAL PATHWAY PROTEINS TO DETERMINE THERAPEUTIC EFFICACY 审中-公开
公开(公告)号：WO2013033623A9
公开(公告)日：2013-03-07
申请号：PCT/US2012/053505
申请日：2012-08-31
申请人： NESTEC S.A. , SINGH, Sharat , KIM, Phillip
发明人： SINGH, Sharat , KIM, Phillip
IPC分类号： G01N33/50 , G01N33/542
摘要： The present invention provides methods for detecting, measuring and quantitating the activation states of components of the PI3K signaling pathway in cells such as tumor cells and selecting an anticancer therapy therewith. The methods involve a collaborative enzyme enhanced reactive-immunoassay (CEER) in which first activation state-independent antibodies specific for one member of a dimerised receptor tyrosine kinase (RTK) pair or a PI3K p110 subunit are labeled with a facilitating moiety (e.g. glucose oxidase) and second activation state-independent or dependent antibodies specific for the other member of the RTK pair or PI3K p85 or PI3K p110 subunit labeled with a signal amplification moiety (e.g. HRP).

3. 发明申请

WO2013086031A1 METHOD OF THERAPY SELECTION FOR PATIENTS WITH CANCER 审中-公开
标题翻译：癌症患者治疗方法选择
公开(公告)号：WO2013086031A1
公开(公告)日：2013-06-13
申请号：PCT/US2012/068005
申请日：2012-12-05
申请人： NESTEC S.A. , SINGH, Sharat
发明人： SINGH, Sharat , KULLER, Anne , LEE, Tani Ann T. , HAZRAR, Saswati , KIRKLAND, Richard , LIU, Xinjun , KIM, Phillip
IPC分类号： G01N33/15 , A61K48/00 , A61P35/00
CPC分类号： G01N33/57484 , G01N33/542 , G01N33/57488 , G01N33/57492 , G01N2800/52
摘要： The present invention provides methods for detecting, measuring and quantitating the expression and activation states of signal transduction analytes in cells such as tumor cells. The invention also provides methods for selecting therapy, optimizing therapy, monitoring therapeutic efficacy, and/or detecting therapeutic resistance. Accordingly, the methods are useful for improving cancer therapy selection and disease monitoring.
摘要翻译：本发明提供了用于检测，测量和定量细胞如肿瘤细胞中信号转导分析物的表达和激活状态的方法。本发明还提供了选择治疗，优化治疗，监测治疗功效和/或检测治疗抗性的方法。因此，该方法可用于改善癌症治疗选择和疾病监测。

4. 发明申请

WO2011008990A1 DRUG SELECTION FOR GASTRIC CANCER THERAPY USING ANTIBODY-BASED ARRAYS 审中-公开
标题翻译：使用基于抗体的阵列进行胃癌治疗的药物选择
公开(公告)号：WO2011008990A1
公开(公告)日：2011-01-20
申请号：PCT/US2010/042182
申请日：2010-07-15
申请人： PROMETHEUS LABORATORIES INC. , SINGH, Sharat , KIM, Phillip , LIU, Xinjun , YBARRONDO, Belen
发明人： SINGH, Sharat , KIM, Phillip , LIU, Xinjun , YBARRONDO, Belen
IPC分类号： G01N33/574
CPC分类号： G01N33/5011 , G01N33/5041
摘要： The present invention provides methods for selecting a suitable anticancer therapy, and for identifying and predicting response for the treatment of a gastric cancer.
摘要翻译：本发明提供了选择合适的抗癌疗法以及鉴定和预测胃癌治疗反应的方法。

5. 发明申请

WO2012138785A1 METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS 审中-公开
标题翻译：预防和改善胃癌患者存活的方法
公开(公告)号：WO2012138785A1
公开(公告)日：2012-10-11
申请号：PCT/US2012/032206
申请日：2012-04-04
申请人： NESTEC SA , KIM, Phillip , SINGH, Sharat
发明人： KIM, Phillip , SINGH, Sharat
IPC分类号： G01N33/574
CPC分类号： G01N33/6893 , A61K31/517 , A61K31/5377 , A61K45/06 , G01N33/57446 , G01N2333/71 , G01N2800/52 , G01N2800/54 , G01N2800/56
摘要： The present invention provides assays and methods for predicting the post-operative survival of a subject having an early stage gastric cancer after tumor surgery. The present invention also provides methods for treating a subject having an early stage gastric cancer by administering a combination therapy tailored to the signal transduction biomarkers that are activated in the cancer. In particular embodiments, the methods of the invention rely on the detection of the activation state or level of a specific combination of signal transducer analytes in a cancer cell obtained from the subject. Thus, the methods of the invention are particularly useful for predicting the survival or prognosis of a subject having an early stage gastric cancer and for guiding both pre- and post-operative treatment decisions by identifying subjects who would benefit from combination therapy as opposed to monotherapy.
摘要翻译：本发明提供了用于预测肿瘤手术后具有早期胃癌的受试者的术后存活的测定和方法。本发明还提供了通过施用针对在癌症中被激活的信号转导生物标志物进行定制的组合疗法来治疗患有早期胃癌的受试者的方法。在具体实施方案中，本发明的方法依赖于从受试者获得的癌细胞中检测信号转导分析物的特定组合的活化状态或水平。因此，本发明的方法对于预测具有早期胃癌的受试者的存活或预后特别有用，并且通过鉴定受益于组合治疗的受试者而不是单一疗法来指导术前和术后治疗决定。

6. 发明申请

WO2009108637A1 DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS 审中-公开
标题翻译：使用基于抗体的阵列进行乳腺癌治疗的药物选择
公开(公告)号：WO2009108637A1
公开(公告)日：2009-09-03
申请号：PCT/US2009/035013
申请日：2009-02-24
申请人： PROMETHEUS LABORATORIES, INC. , SINGH, Sharat , HARVEY, Jeanne , KIM, Phillip , LIU, Xinjun , LIU, Limin , BARHAM, Robert , NERI, Bruce
发明人： SINGH, Sharat , HARVEY, Jeanne , KIM, Phillip , LIU, Xinjun , LIU, Limin , BARHAM, Robert , NERI, Bruce
IPC分类号： G01N33/50
CPC分类号： G01N33/57415 , G01N33/5011 , G01N2800/52 , G01N2800/60
摘要： The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供用于检测肿瘤细胞中信号转导途径的组分的激活状态的组合物和方法。关于使用本发明的信号转导途径的组分的激活状态的信息可用于癌症诊断，预后和癌症治疗的设计。

7. 发明申请

WO2011088149A2 METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY 审中-公开
标题翻译：预测三阴性乳腺癌对治疗反应的方法
公开(公告)号：WO2011088149A2
公开(公告)日：2011-07-21
申请号：PCT/US2011/021026
申请日：2011-01-12
申请人： PROMETHEUS LABORATORIES INC. , LIU, Xinjun , KIM, Phillip , KIRKLAND, Richard , LEE, Tani , YBARRONDO, Belen , SINGH, Sharat
发明人： LIU, Xinjun , KIM, Phillip , KIRKLAND, Richard , LEE, Tani , YBARRONDO, Belen , SINGH, Sharat
CPC分类号： G01N33/57415 , G01N2333/71 , G01N2800/52
摘要： The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供了用于检测肿瘤细胞中的信号转导途径组分例如三阴性转移性乳腺肿瘤细胞的组分和/或活化水平的组合物和方法。关于源自使用本发明的信号转导途径组分的表达和/或活化水平的信息可用于癌症诊断，预后和癌症治疗的设计。

8. 发明申请

WO2008036802A2 ANTIBODY-BASED ARRAYS FOR DETECTING MULTIPLE SIGNAL TRANSDUCERS IN RARE CIRCULATING CELLS 审中-公开
标题翻译：用于检测稀有循环细胞中多个信号传感器的基于抗体的阵列
公开(公告)号：WO2008036802A2
公开(公告)日：2008-03-27
申请号：PCT/US2007/079002
申请日：2007-09-20
申请人： PROMETHEUS LABORATORIES INC. , HARVEY, Jeanne , SINGH, Sharat , KIM, Phillip , LIU, Xinjun , BARHAM, Robert , LIU, Limin
发明人： HARVEY, Jeanne , SINGH, Sharat , KIM, Phillip , LIU, Xinjun , BARHAM, Robert , LIU, Limin
IPC分类号： G01N33/50
CPC分类号： G01N33/57484 , G01N33/54306
摘要： The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
摘要翻译：本发明提供了用于检测罕见循环细胞中多种信号转导分子的活化状态和/或总量的基于抗体的阵列及其用于促进癌症预后和诊断的方法以及个性化，有针对性的治疗设计。

9. 发明申请

WO2010132723A1 BIOMARKERS FOR DETERMINING SENSITIVITY OF BREAST CANCER CELLS TO HER2-TARGETED THERAPY 审中-公开
标题翻译：用于确定乳腺癌细胞对HER2靶向治疗敏感性的生物标志物
公开(公告)号：WO2010132723A1
公开(公告)日：2010-11-18
申请号：PCT/US2010/034814
申请日：2010-05-13
申请人： PROMETHEUS LABORATORIES INC. , KIM, Phillip , LIU, Xinjun , KIRKLAND, Richard , LEE, Tani , YBARRONDO, Belen , SINGH, Sharat
发明人： KIM, Phillip , LIU, Xinjun , KIRKLAND, Richard , LEE, Tani , YBARRONDO, Belen , SINGH, Sharat
IPC分类号： G01N33/50 , G01N33/532 , G01N33/533 , G01N33/535 , G01N33/543 , G01N33/574
CPC分类号： G01N33/57415 , G01N33/5011 , G01N2800/52
摘要： The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
摘要翻译：本发明提供用于检测诸如肿瘤细胞的细胞中信号转导途径的组分的表达和/或激活状态的组合物和方法。关于衍生自本发明的信号转导途径的组分的表达和/或激活状态的信息可用于癌症诊断，预后和癌症治疗的设计。

10. 发明申请

WO2014122582A1 DRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPY 审中-公开
标题翻译：非小细胞肺癌治疗药物选择
公开(公告)号：WO2014122582A1
公开(公告)日：2014-08-14
申请号：PCT/IB2014/058790
申请日：2014-02-04
申请人： NESTEC S.A.
发明人： SINGH, Sharat , KIM, Phillip
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/57423 , G01N33/5748 , G01N2333/71 , G01N2333/82 , G01N2800/52
摘要： The present invention provides methods for selecting a suitable anticancer drag for the treatment of patient with non-small cell lung cancer (NSCLC), The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
摘要翻译：本发明提供了用于选择用于治疗非小细胞肺癌（NSCLC）患者的合适的抗癌阻力的方法。本发明还提供了用于测定接受EGFR抑制剂治疗的NSCLC患者耐药性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式